secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001140361-25-033668
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics appoints Robert Gagnon as CFO effective September 2, 2025
-----------------------------------------------------------------------

- Annual base salary of $465,000, eligible for annual bonus up to 45% of base.
- Stock option for 250,000 shares and restricted stock award for 200,000 shares, both vesting over four years.
- Gagnon previously CFO of Remix Therapeutics and Verastem Oncology; has raised over $2B in capital.
- Appointment is part of Opus's advancement of clinical pipeline for inherited retinal diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/0001140361-25-033668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/ef20054946_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-033668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer